Delays For Discovery Lab's Surfaxin

Shares of Discovery Laboratories Inc. (DSCO) plummeted $2.49 to close at $2.20 after the Food and Drug Administration requested additional process validation for the company's premature infant lung disease treatment Surfaxin.